This research shows that doxorubicin disrupts immune signaling between the spleen and heart, priming inflammatory cells that worsen cardiac damage when hypertension develops later in life. Using a two-hit mouse model, the work reveals a heart–spleen axis and identifies immune cells as targets to protect childhood cancer survivors from heart failure.

Chronic diseases exhaust the body’s CD8 T cells, weakening their ability to fight infections and cancer. This research identifies CD7 as a key driver of T-cell exhaustion. Removing CD7 keeps T cells active, boosts cytokine production, and improves control of tumors and viruses—offering a promising new immunotherapy target.

This research investigates how T cells influence microglial behavior in Alzheimer’s disease. Using a mouse model, the study found that removing T cells did not alter amyloid-beta plaques but unexpectedly led to healthier microglial activity and reduced myelin damage. The findings suggest T cells may worsen neurodegeneration and reveal new therapeutic avenues.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.